EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
EZH2 suppression diversifies prostate cancer lineage plasticity, which has implications for EZH2-targeted therapies that are being evaluated for prostate cancer treatment. See related commentary by Thienger et al., p. 827.
Authors
- Paloma Cejas (ORCID: https://orcid.org/0000-0002-2090-7748)
- David W. Goodrich (ORCID: https://orcid.org/0000-0002-1021-1827)
- Shweta Kukreja (ORCID: https://orcid.org/0000-0001-6794-9016)
- Mark D. Long (ORCID: https://orcid.org/0000-0003-1120-8176)
- Kristine M. Wadosky (ORCID: https://orcid.org/0000-0003-3952-9377)
- Eduardo Cortes Gomez (ORCID: https://orcid.org/0000-0002-0966-6488)
- Henry W. Long (ORCID: https://orcid.org/0000-0001-6849-6629)
- Yanqing Wang (ORCID: https://orcid.org/0009-0006-7828-9977)
- Justine J. Jacobi (ORCID: https://orcid.org/0000-0002-9109-3294)
- Neha Jaiswal (ORCID: https://orcid.org/0000-0002-1836-6911)
- Jianmin Wang (ORCID: https://orcid.org/0000-0001-7527-0409)
- Bo Xu (ORCID: https://orcid.org/0000-0003-1201-7558)
- Prashant K. Singh (ORCID: https://orcid.org/0000-0001-5649-8424)
- Jie Wang (ORCID: https://orcid.org/0000-0001-5949-1906)
- Xueji Zhang (ORCID: https://orcid.org/0009-0000-9811-4900)
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1158/0008-5472.can-25-2747
- Citations
- 1
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.81